Impact of pegylated interferon α-2B and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: An open-label series

Liver International

Volumn 26, Issue 5, 2006, Pages 529-535

  Mukherjee, Sandeep ^a   Lyden, Elizabeth ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Fibrosis; Pegylated interferon; Recurrent hepatitis C; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; CYCLOSPORIN A; FOLIC ACID; METHYLPREDNISOLONE; PEGINTERFERON ALPHA2B; RIBAVIRIN; TACROLIMUS; VIRUS RNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTERY THROMBOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEPATIC ARTERY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER TOXICITY; LIVER TRANSPLANTATION; MAINTENANCE THERAPY; MALE; PLEURA EFFUSION; PSYCHOSIS; RECURRENT INFECTION; RNA ANALYSIS; SCORING SYSTEM; THROMBOCYTOPENIA; TREATMENT FAILURE;

ADULT; AGED; BIOPSY; COHORT STUDIES; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; FEMALE; HEPATITIS C; HUMANS; INTERFERON ALFA-2B; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECURRENCE; REMISSION INDUCTION; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 33646813936     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2006.01261.x     Document Type: Article

References (31)

1. Kim W R. The burden of hepatitis C in the United States. Hepatology 2002; 36 (Suppl. 1): S30-4.
2. Gruener N H, Jung M C, Schirren C A. Recurrent hepatitis C virus infection after liver transplantation: Natural course, therapeutic approaches and possible mechanisms of viral control. Antimicrob Chemother 2004; 54: 17-20.
3. Forman L M. To transplant or not to retransplant recurrnet hepatitis C and liver failure. Clin Liv Dis 2003; 7: 615-29.
4. Everson G T, Trotter J, Forman L, et al. Treatment of advanced hepatitis C with a low dose accelerating dosage regimen of anti-viral therapy. Hepatology 2005; 42: 255-62.
5. Berenguer M. Treatment of hepatitis C after liver transplantation. Clin Liv Dis 2005; 4: 579-600.
6. Firpi R J, Abdelmalek M F, Soldevila-Pico C, et al. One year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transplant 2004; 10: 1240-7.
7. Mukherjee S, Rogge J, Weaver L, Schafer D F. Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation. Transplant Proc 2003; 35: 3042-4.
8. Regev A, Molina E, Moura R, et al. Reliability of histopathologic assessment for the differentiation of recurrent hepatitis C from acute rejection after liver transplantation. Liver Transplant 2004; 10: 1233-9.
9. Batts K P, Ludwig J. Chronic hepatitis: An update on terminology and reporting. Am J Surg Pathol 1995; 19: 1409-17.
10. Feray C, Samuel D, Gigou M, et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: Antiviral effects and risk of rejection. Hepatology 1995; 22: 1084-9.
11. Samuel D, Bizollon T, Feray C, et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: A randomized study. Gastroenterology 2003; 124: 642-50.
12. Rodriguez-Luna H, Vargas H E. Management of hepatitis C infection in the setting of liver transplantation. Liver Transplant 2005; 11: 475-89.
13. Babatin M, Schindel L, Burak K W. Pegylated-interferon alpha 2b and ribavirin for recurrent hepatitis C after liver transplantation: From a Canadian experience to recommendations for therapy. Can J Gastroenterol 2005; 19: 359-65.
14. Biselli M, Andreone P, Gramenzi A, et al. Pegylated interferon plus ribavirin for recurrent hepatitis C infection after liver transplantationin naïve and non-responder patients on a stable immunosuppressive regimen. Dig Liv Dis 2006; 38: 27-32.
15. Mukherjee S, Gilroy R K, Mccashland T M, Schafer D F. Pegylated interferon for recurrent hepatitis C in liver transplant recipients with renal failure: A prospective cohort study. Transplant Proc 2003; 35: 1478-9.
16. Lavezzo B, Franchello A, Smedile A, et al. Treatment of recurrent hepatitis C in liver transplants: Efficacy of a six versus twelve month course of interferon alfa 2b with ribavirin. J Hepatol 2002; 37: 247-52.
17. Samonakis D N, Cholongitas E, Triantos C K, et al. Sustained spontaneous disappearance of serum HCV-RNA under immunosuppression after liver transplantation for HCV cirrhosis. J Hepatol 2005; 43: 1091-3.
18. Rodriguez-Luna H, Khatib A, Sharma P, et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: An open-label series. Transplantation 2004; 77: 190-4.
19. Dumortier J, Scoazec J Y, Chevallier P, Boilliot O. Treatment of recurrent hepatitis C after liver transplantation: A pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004; 40: 669-74.
20. Neff G W, Montalbano M, O'Brien C B, et al. Treatment of established recurrent HCV in liver transplant recipients with pegylated interferon-alfa2b and ribavirin therapy. Transplantation 2004; 78: 1303-7.
21. Chalasani N, Manzarbeita C, Ferenci P, et al. Peginterferon alfa-2a and ribavirin for hepatitis C after liver transplantation: Two, randomized controlled trials. Hepatology 2005; 41: 289-98.
22. Toniutto P, Fabris C, Fumo E, et al. Pegylated versus standard interferon alfa-2a in anti-viral regimens for post-transplant recurrent HCV: Comparison of tolerability and efficacy. J Gastroenterol Hepatol 2005; 20: 577-82.
23. Abdelmalek M F, Firpi R J, Soldevida-Pico C, et al. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transplant 2004; 10: 199-207.
24. Regev A, Berho M, Jeffers L J, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-8.
25. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporine A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatolgoy 2003; 38: 1282-8.
26. Firpi R J, Zhu H, Moulli G, et al. Cyclosporine suppresses hepatitis C in vitro and increases the chance of sustained virological response after liver transplantation. Liver Transplant 2006; 12: 51-7.
27. Martin P, Busuttil R W, Goldstein R M, et al. Impact of tacrolimus versus cyclosporine in hepatitis C infected liver transplant recipients on recurrent hepatitis C: A prospective, randomized trial. Liver Transplant 2004; 10: 1258-62.
28. Levy G, Villamil F, Samuel D, et al. Results of list 2, a multicenter, randomized study comparing cyclosporine emulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation 2004; 77: 1632-8.
29. Afdhal N H, Dieterich D T, Pockros P J, et al. Epoietin alfa maintaines ribavirin dose in HCV-infected patients: A prospective, double-blind, randomized, controlled study. Gastroenterology 2004; 126: 1302-11.
30. Curry M P, Afdhal N H. Use of growth factors with anti-viral therapy for chronic hepatitis C. Clin Liv Dis 2005; 9: 439-51.
31. Kuo A, Terrault N H. Management of hepatitis C in liver transplant recipients. Am J Transplant 2006; 6: 449-58.